What oncoclínicas&co does

Oncoclínicas&Co operates one of the largest dedicated oncology care networks in Brazil, delivering comprehensive cancer diagnosis and treatment through more than 140 owned clinics, laboratories, and integrated cancer treatment centers across 40 cities. The legal entity, ONCOCLINICAS DO BRASIL SERV MEDICOS SA, is headquartered in São Paulo and offers the full adult and pediatric oncology pathway, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, cell therapy, bone marrow transplant, surgery, palliative care, and clinical trials. Patient-facing channels include a corporate website, a mobile app on Google Play and App Store, a patient portal, telemedicine, and dedicated portals for internal and external referring physicians. The network is supported by an ecosystem of medical education and research assets, notably OC Academia, OC Journal, and Instituto Oncoclínicas.

The technological centerpiece is OC Medicina de Precisão, a precision medicine platform that combines artificial intelligence, genomic analysis, and digital pathology to support treatment individualization. Supporting diagnostic products include the proprietary Onco-PDO test, the Jornada Molecular (Molecular Journey) pathway for comprehensive genomic profiling, genetic testing services, and digital pathology integrated with AI image analysis. AI capabilities disclosed are computer vision for pathology image interpretation and predictive analytics for genomic data, though no proprietary models, patents, or research publications are named.

Revenue is generated across four streams: medical services (consultations, chemotherapy, radiotherapy, surgeries, immunotherapy, targeted therapy, bone marrow transplant), diagnostic testing (pathology, genetics, molecular diagnostics, Onco-PDO), telemedicine, and clinical research. Services are distributed through a direct-to-consumer model via the owned clinic network, supplemented by digital channels (mobile app, patient portal, telemedicine), and are reimbursed through Brazilian health insurance plans (convênios). Pricing is quote-based per procedure and not publicly disclosed. Customer segmentation is by patient persona — oncology patients, referring physicians, and pediatric oncology patients — with no enterprise logos, ARR, or concentration data available.

Name

oncoclínicas&co

Legal name

ONCOCLINICAS DO BRASIL SERV MEDICOS SA

Website

https://oncoclinicas.com

Company type

Private

Operating status

Operating

Short description

Oncoclínicas&Co is a Brazilian oncology care network operating 140+ clinics and laboratories across 40 cities, delivering chemotherapy, radiotherapy, immunotherapy, and precision medicine diagnostics to cancer patients through its OC Medicina de Precisão platform.

Ownership category

akta.pro rank

Product category

Oncology Healthcare Services

NAICS

Offices of Physicians (62111), Medical Laboratories (621511), Other Ambulatory Health Care Services (6219)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), In Vitro & In Vivo Diagnostic Substances (2835), Services-Health Services (8000)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Oncology Telemedicine Platforms (HLALAGAH), Medical Oncology (HLAKAFAB), Oncology & Cancer Specialty Hospitals (HLAFAHAC)

Keywords

• Oncology treatment services
• Precision medicine platform
• Cancer diagnostic testing
• Radiotherapy chemotherapy services
• Digital pathology AI

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Services Revenue: Oncoclínicas generates revenue through providing comprehensive oncology medical services including consultations, diagnostics, chemotherapy, radiotherapy, surgeries, immunotherapy, targeted therapy, bone marrow transplants, and other cancer treatments across its network of 140+ units.
2. Diagnostic Testing Services: Revenue from pathological analysis, genetic testing, molecular diagnostics, and the Onco-PDO test performed at the company's laboratories and precision medicine centers.
3. Telemedicine Services: Revenue from telemedicine consultations and remote patient care services.
4. Clinical Research: Revenue from clinical trials and research programs conducted across the organization's facilities.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Oncoclínicas&Co provides comprehensive cancer diagnosis, treatment, and supportive care through a network of more than 140 clinics, laboratories, and integrated cancer treatment centers across 40 Brazilian cities. The portfolio spans chemotherapy, radiotherapy, immunotherapy, targeted therapy, cell therapy, bone marrow transplant, oncological surgery, and pediatric oncology, supported by the proprietary OC Medicina de Precisão platform that integrates artificial intelligence, genomics, and digital pathology for personalized treatment selection.

Product overview

Oncoclínicas&Co operates as a comprehensive oncology healthcare network offering an integrated platform of cancer treatment services and precision medicine solutions. The portfolio includes core treatment services (chemotherapy, radiotherapy, immunotherapy, targeted therapy, cell therapy, bone marrow transplant), diagnostic services (precision medicine with AI and digital pathology, genetic testing, Onco-PDO test, molecular journey), patient support services (telemedicine, patient navigation, palliative care, pediatric oncology), and educational/research initiatives (Instituto Oncoclínicas, OC Academia, OC Journal). The OC Medicina de Precisão platform serves as the technological hub, integrating artificial intelligence, genomics, and digital pathology to accelerate personalized cancer care.

Differentiator

Problem solved

Functional benefit

Brands

• OC Medicina de Precisão: Precision medicine division combining artificial intelligence, genomics, and digital pathology to support oncology specialists and accelerate patient care.

Products and services

• OC Medicina de Precisão (Precision Medicine)

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hospital de Amor (formerly Hospital de Câncer de Barretos): Large Brazilian cancer specialty hospital network with multiple units providing comprehensive oncology care, clinical research, and prevention services, directly comparable to Oncoclínicas's network and mission.
• A.C. Camargo Cancer Center: One of Brazil's leading oncology specialty hospitals based in São Paulo, offering diagnosis, treatment, research, and education services comparable to Oncoclínicas's full-spectrum oncology model.

Broad incumbents

• Hospital Israelita Albert Einstein: Premium Brazilian hospital and health system operating a significant oncology program among broader multi-specialty services, competing for the same high-acuity oncology patients in São Paulo and other major metros.
• Hospital Sírio-Libanês: High-end São Paulo-based hospital with established oncology center and precision medicine offerings, serving a similar premium patient segment and competing for specialist talent and referrals.
• UnitedHealth Group (Optum): Global diversified health services company with significant oncology care delivery, value-based care, and data/analytics capabilities that intersect with Oncoclínicas's integrated oncology-plus-precision-medicine model.
• Rede D'Or São Luiz: Largest private hospital network in Brazil with extensive oncology capabilities across its facilities, competing for insured patients and physician referrals in the same metropolitan markets as Oncoclínicas.

Emerging players

• Foundation Medicine (Roche): Specialized molecular profiling and genomic testing company for cancer treatment selection, closely comparable to Oncoclínicas's Jornada Molecular and Onco-PDO testing services.
• Tempus AI: US-based AI-driven precision medicine company offering genomic sequencing, molecular profiling, and data analytics for oncology, comparable to the OC Medicina de Precisão platform's technology approach.

Others

• Dasa (Diagnósticos da América): Largest diagnostic medicine company in Brazil with extensive laboratory, imaging, and genomic testing capabilities that overlap with Oncoclínicas's diagnostic and precision medicine service lines.

Regional players

• City of Hope: US-based comprehensive cancer center with research, treatment, and precision medicine programs; comparable as a regional oncology specialty network outside of Oncoclínicas's Brazilian market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCTLjB1xqQs88RiW1JsQHDpQ
• Facebookfacebook.com/GrupoOncoclinicas
• LinkedInlinkedin.com/company/rede-oncocl%C3%ADnicas-do-brasil?trk=cws-btn-overview-0-0
• Instagraminstagram.com/grupooncoclinicas
• TikToktiktok.com/@oncoclinicas

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about oncoclínicas&co